Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.7%

24 terminated/withdrawn out of 163 trials

Success Rate

82.7%

-3.8% vs industry average

Late-Stage Pipeline

8 trials in Phase 3/4

Results Transparency

29%

33 of 115 completed trials have results

Key Signals

9 recruiting33 with results19 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 1

46(36.8%)

N/A

45(36.0%)

Phase 2

15(12.0%)

Early Phase 1

11(8.8%)

Phase 4

6(4.8%)

Phase 3

2(1.6%)

125Total

Phase 1(46)

N/A(45)

Phase 2(15)

Early Phase 1(11)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (163)

Showing 20 of 163 trials

NCT04340596Phase 1Active Not Recruiting

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Role: collaborator

NCT03282344Phase 2Active Not Recruiting

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Role: collaborator

NCT03458780Completed

Yellow Fever Immune Response at Single Cell Resolution

Role: lead

NCT06035549Completed

Resilience in East Asian Immigrants for Advance Care Planning Discussions

Role: collaborator

NCT03523377Not ApplicableActive Not Recruiting

Overnight Fasting After Completion of Therapy: The OnFACT Study

Role: collaborator

NCT04547777Phase 1Recruiting

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Role: collaborator

NCT05050240Not ApplicableActive Not Recruiting

BATokines as Biomarkers of Brown Fat in Humans

Role: lead

NCT03254277Phase 1Completed

3BNC117-LS First-in-Human Phase 1 Study

Role: lead

NCT05126472Phase 1Recruiting

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Role: collaborator

NCT00580385Not ApplicableActive Not Recruiting

Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors

Role: collaborator

NCT01782703Active Not Recruiting

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

Role: collaborator

NCT02051114Active Not Recruiting

Discovering the Antecedents of Rheumatoid Arthritis Flare

Role: lead

NCT05272735Phase 4Terminated

HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers

Role: lead

NCT06424132Not ApplicableActive Not Recruiting

Thermogenic Silencer Regulatory Factors in Humans

Role: lead

NCT06146218Not ApplicableCompleted

Compassion-Based Resiliency Training (CBRT) Intervention on Racism-based Stress

Role: lead

NCT05245292Phase 1Completed

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Role: lead

NCT05834036Phase 4Completed

Effect of Antibiotics on Enteric Neurons and Glia

Role: lead

NCT00578240Active Not Recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Role: collaborator

NCT04357821Phase 1Active Not Recruiting

Combinatorial Therapy to Induce an HIV Remission

Role: collaborator

NCT05856890Phase 1Recruiting

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

Role: lead